If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

  • There is currently no data for DEMG

Grant of options

12 Jun 2009 09:22

RNS Number : 8037T
Deltex Medical Group PLC
12 June 2009
 



Deltex Medical Group plc

Grant of options

12 June 2009 - Deltex Medical Group plc ("the Company"), the global leader in oesophageal Doppler monitoring ("ODM"), announces that the Board has today approved the issue of share options to its executive members.

Employee Share Option Scheme

The Board has approved the issue of contractual share options to Andy Hill, Chief Executive, and Ewan Phillips, Finance Director, under the Company's 2001 Executive Share Option Scheme as follows:

Name

Number

Exercise

Price £

Exercise period 

Total Number of options held

 

 

 

 

 

Andy Hill

500,000

0.1275

2012 - 2019

2,600,000

 

 

 

 

 

Ewan Phillips

500,000

0.1275

2012 - 2019

2,480,000

EMI scheme - Cash bonus sacrifice

In addition, the Company's 2003 Enterprise Management Incentive Scheme ('EMI Scheme') allows directors and employees who have earned performance related bonus payments under the terms of their employment to sacrifice their entitlement to cash payment in return for share options at the nominal value of 1p per share. The EMI Scheme is designed to allow managers to align their interests with those of shareholders by building a meaningful equity interest in the Company while preserving the Company's cash resources for investment in its operations. In the event that the share price on exercise and sale of an EMI Scheme option share is higher than at the date of bonus sacrifice, the EMI Scheme is potentially tax efficient for the scheme member. However, if the share price on exercise and sale of an EMI Scheme option share is lower than at the date of award, the individual will realise an amount after tax that is lower than the amount of bonus originally sacrificed.

Andy Hill and Ewan Phillips have both elected to sacrifice the whole of the performance bonuses (£60,000 each) awarded by the Company's Remuneration Committee in respect of the year ended 31 December 2008, resulting in awards of options under the EMI Scheme as follows

 

Name

Number

Exercise

Price £

Exercise period 

Total Number of options held

 

 

 

 

 

Andy Hill

510,638

0.01

2009 - 2019

1,583,696

 

 

 

 

 

Ewan Phillips

510,638

0.01

2009 - 2019

2,088,754

 

 Additional interest

Mr Hill also has a beneficial interest in 179,334 ordinary shares in the Company representing 0.18 per cent of the issued ordinary share capital of the Company.

 

Mr Phillips also has a beneficial interest in 977,156 ordinary shares in the Company representing 0.96 per cent of the issued ordinary share capital of the Company.

All shares and options relate to ordinary 1p shares

For further information, please contact:-

Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman  Andy Hill, Chief Executive Ewan Phillips, Finance Director

Nominated Adviser and Broker 0207 398 1600

Arden Partners plc

Christopher Hardie

Matthew Armitt

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSIIFFTRIIFLIA
Date   Source Headline
8th Sep 20167:00 amRNSThree new US platform programme accounts
8th Sep 20167:00 amRNSInterim results
15th Aug 201611:10 amRNSHolding(s) in Company
15th Jul 20164:00 pmRNSHolding(s) in Company
11th Jul 20167:00 amRNSResults from head to head trial presented
8th Jul 20167:00 amRNSPre-close Trading Update
1st Jul 20168:19 amRNSShare Subscription
17th Jun 20164:10 pmRNSDirector/PDMR Shareholding
9th Jun 20167:00 amRNSTwo new accounts added to US platform programme
1st Jun 20167:00 amRNSODM adopted into clinical guidelines in Spain
12th May 20161:10 pmRNSResult of AGM
12th May 20169:30 amRNSDirector/PDMR Shareholding
12th May 20167:01 amRNSTwo US accounts added to platform programme
12th May 20167:00 amRNSAGM Statement
4th May 20167:00 amRNSEnhanced performance TruFlow probe launched in UK
20th Apr 20163:25 pmRNSPosting of Annual Report and Notice of AGM
5th Apr 20167:00 amRNSTwo new US platform programme accounts opened
10th Mar 20167:00 amRNSPlacing and Issue of Shares
2nd Mar 20161:01 pmRNSHolding(s) in Company
25th Feb 201611:00 amRNSResult of General Meeting
23rd Feb 20167:00 amRNSResult of the Open Offer
8th Feb 20167:00 amRNSPosting of Circular
3rd Feb 20167:00 amRNSPlacing and issue of new convertible loan notes
27th Jan 20167:00 amRNSNew US platform programme account opened
27th Jan 20167:00 amRNSTrading Update
9th Dec 20157:00 amRNSTwo new US platform programme accounts opened
23rd Nov 20157:00 amRNSTwo new US platform programme accounts opened
20th Nov 20157:00 amRNSUS fluid variation study published by Premier
18th Nov 20157:00 amRNSOpen access e-learning courses launched
12th Nov 20157:00 amRNSNew US Platform Programme Account Opened
16th Sep 20157:00 amRNSInterim Results
9th Sep 20157:00 amRNSNew US platform programme account opened
21st Aug 201510:40 amRNSHolding(s) in Company
29th Jul 20157:00 amRNSFDA approves paediatric probes for launch in USA
28th Jul 20151:40 pmRNSAdditional Listing
14th Jul 20157:00 amRNSPre-close Trading Update
14th Jul 20157:00 amRNSCanadian tender won
1st Jul 20154:45 pmRNSDirector/PDMR Shareholding
30th Jun 20157:00 amRNSNew US platform programme account opened
24th Jun 20157:00 amRNSNew UK Government R&D funding secured
23rd Jun 20158:00 amRNSAdditional Listing
23rd Jun 20157:00 amRNSDeltex appoints new Group Finance Director
15th Jun 20157:00 amRNSGrant of options
12th Jun 20151:58 pmRNSHolding(s) in Company
9th Jun 20157:00 amRNSLeading US hospital improves surgical outcomes
2nd Jun 20157:00 amRNSBoard Changes
22nd May 201510:25 amRNSDirector Shareholding
12th May 20151:01 pmRNSResult of AGM
6th May 20158:00 amRNSDirectors' Shareholdings/Issue of equity
6th May 20157:02 amRNSFirst US 'remote training' account

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.